Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy

Authors:

J.Wang, J.Xiu,Y.Baca, H.Arai, F.Battaglin, N.Kawanishi, S.Soni, W.Zhang, J.Millstein, A.F.Shields, A.Grothey, B.A.Weinberg, J.L.Marshall, E.Lou, M.Khushman, D.P.S.Sohal, M. J.Hall, M.Oberley, H.J.Lenz

Highlights:

1. GEA tumors with mutations in KRAS, TP53 and RAS-MAPK pathway are associated with high PD-L1 CPS in the pMMR&MSS subgroup.
2. RAS-MAPK pathway alteration may be a positive predictor and TP53 mutation a negative predictor for ICI efficacy in GEA.
3. RAS-MAPK pathway alteration and TP53 mutation are positively and negatively, respectively, associated with tumor immunity.

External Link